

## Introduction

Hepatocellular Carcinoma (HCC) is a potential complication of cirrhosis. Liver transplantation is often viewed as curative of HCC when fulfilling the Milan criteria prior to surgery. The 5-year survival rate post-transplant is around 80%. However, recurrence rates of HCC posttransplant remain high at 15-20%. Recurrence is generally discovers upon surveillance imaging. HCC causing gastric ulceration by direct extension of primary tumor has been previously described, however, recurrence as a gastric ulcer is rare. Here, we present a case of post-transplant HCC recurrence presenting as a bleeding gastric ulcer.

# Contact

Alex Blachowicz Loyola University Medical Center Email: <u>alexander.Blachowicz@luhs.org</u> Phone: 708-581-0676

# A Rare Case of HCC Recurrence as a Bleeding Gastric Ulcer

Alex Blachowicz, MD<sup>1</sup>; Marcel Ghanim, MD<sup>1</sup>; Steven Hendler, MD<sup>1</sup>, <sup>1</sup>Loyola University Medical Center

#### **Case Description**

A 72-year-old Caucasian female presented with coffee-ground emesis. Three years prior, she had orthotopic liver transplantation due to hepatitis C virus (HCV) related cirrhosis, previously treated with Vosevi/ribavarin with sustained virologic response and HCC with evidence of moderate differentiation and focus of vascular invasion on explanted liver.

Upper endoscopy revealed a cratered gastric ulcer with heaped edges and an adherent clot in the antrum. Biopsies from the ulcer edges showed poorly differentiated adenocarcinoma with signet ring features. Immunohistochemical testing showed tumor cells positive for CK8/18, Glutamine Synthetase, and polyclonal CEA with canalicular pattern; features consistent with high grade HCC.

CT scan revealed a necrotic mass replacing most of the pancreatic body and tail with tumor thrombus involving the splenic vein and main portal vein, a lung mass approximately 7 x 10 cm and multiple vertebral compression fractures. Fine needle biopsy of pancreatic mass was consistent with metastatic carcinoma compatible with HCC.

#### Discussion

Tumor recurrence post-liver transplantation is noted in 15-20% of cases after 5 years. Factors related to HCC tumor recurrence include: staging of tumor, vascular invasion, AFP levels prior to transplant, wait time to transplant, ischemia time, and donor characteristics. Notably, macro- and microvascular invasion decreased 5-year recurrence-free survival (44% and 13%, respectively), compared to 64% in patients without vascular invasion.

There is no clear consensus for Standard posttransplantation monitoring. A multi-center study has proposed a protocol using the RETREAT (Risk Estimation of Tumor Recurrence Post-Transplantation) scoring system for determining screening of HCC recurrence. This includes: AFP levels prior to transplant (max score of 3 for AFP >1000), vascular invasion (max score of 2 for any evidence of invasion), and sum of the diameters of HCC lesions (max score of 3 for sum >10). In our patient, with <u>microvascular</u> <u>invasion</u>, a score of 2 would standardize her to screening every 6 months for 2 years which was consistent with the monitoring she had.

The median time to HCC tumor recurrence is within 12-16 months post-transplantation, with over 75% occurring in first 2 years. Initial presentation of HCC recurrence as a direct gastrointestinal invasion is exceeding rare. There have been few case reports describing similar presentations as in our case, however, none have occurred after liver transplantation. Given its rarity, differential diagnosis of gastric ulcers in patients with history of HCC should include metastatic disease.

### References

 Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Uver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhoist. N Engl J Med. 1996;334:693–699. doi: 10.1056/WEM.199603143341104.

2 Camar AA, Ukomadu C. Uker Neoplasms. In: Greenberger NJ, Blumberg RS, Burakoff R. eds. CURRNT Diagnosis Ramp: Treatment: Gastroenterology, Hepatology, Ramp; Endoscopy, 3e. McG Hill: 2016. Accessed May 06, 2022 https://accessed.org/ac.ml/accessed.McG com archer.luhr.org/content.aspi//bookid=16218amp;sectionid=105187385

3 Long 1, Lang ZW, Wang HS, Wang TL, Wang EE, Liu SQ, Guitamine synthesize as an early marker for hepatocellular cancellular particular based on potenomic analysis of resceted mult hepatocellular cancellular particular particular based biol. 2015;93:136-56.
4 Kalehabi A, Inoue M, Wei M, Fakuhama S, Vannbuchh H. Cytokeratin §/18 overopression and complex formation as an indicator of GST # possible for transformation into hepatocellular carcinome. Taxick appl Harmanol. 2003;93:11/77-36 doi:10.1018/j.pa.2009.04.018

5 Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Verizi H, Finn RS, Tong M, Histi JR, Busutti RW. A novel prognostic nonogram accurately predicts hepatocellular carrinoma recurrences after low transplantation: naisylis of 865 consecutive live transplant recipients. J Am Coll Surg. 2015;22:0416–427. doi: 10.106/j.jamcklurg.2014.12.025

6 Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurr After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3(4):493-500. doi:10.1001/jamaoncol.2016.5116

7 Figuries NA. Hepstechtigker zersionen sersierens after Iver transformtions Risk factors, screening and nicial generations. Vol 10:4114/j.241.272.
doi:10.4724/wjh.v11.12.61
8 Naga S, Manga RS, Kuld CJ, et al. Prognosis after recurrence of hepstocellular carcinons in lower transformation: prediction for seasceald treatment and survival. Clin Transplant. 2013;37(1):135-116. doi:10.1111/j.11244
9 Synch P, Green L, Jordan PH, Graham DV. Hepstocellular carcinoma metabatic to the stomach presenting as bleeding multiple careful carcins. 2013;47(1):155-116. doi:10.1111/j.11244
9 Synch P, Green L, Jordan PH, Graham DV. Hepstocellular carcinoma metabatic to the stomach presenting as a bleeding multiple careful carc. Journal and survivo of the surgical management word 10.63014/26-35. doi:10.3714/01.3124.35.2612.01211/j.11244





B. Pancreatic Mass

C. Lung Mass